Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US
Shots:
- EyePoint to receive $75M up front, $7.5M in quarterly installments during 2024 along with royalties from 2025 to 2028 based on net revenues in the US from Iluvien & Yutiq. EyePoint will transfer & assign to Alimera certain assets & certain contracts with third parties related to Yutiq incl. the new drug application for Yutiq
- Alimera gets an exclusive global right to Yutiq for chronic non-infectious uveitis excl. China, Hong Kong, Taiwan, Macau, South Korea & Southeast Asia. EyePoint has a pre-existing license with Ocumension Therapeutics
- Alimera used a $69M private placement of Series B preferred stock & common stock and borrowing of an additional $20M through an amendment to its existing term loan agreement with SLR Capital Partners
Ref: Globe Newswire | Image: Alimera
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
